Close
Close
Treatment News

Vanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book

2.5
2.5 from 2 votes
Friday, September 21, 2018

WASHINGTON - Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced that a HETLIOZ® patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The '977 patent was issued by the United States Patent and Trademark Office on September 11, 2018 and expires in February 2035. Prior to this newly listed '977 patent, the HETLIOZ® Orange Book listed patent with the latest expiry date was set to expire in May 2034.

About Vanda
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com.

Contact:
Jim Kelly
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Source: Vanda Pharmaceuticals Inc.
2.5
2.5 from 2 votes
Free Newsletter
Trending News
Related Videos
by Abidemi Uruejoma
9,087 views
by Abidemi Uruejoma
10,061 views